Fresenius executes pact for Interface Biologics license

Fresenius Medical Care (NYSE:FMS), the world’s largest integrated provider of dialysis products and services, has executed an option for an exclusive license to apply Interface Biologics’ Endexo technology to various components of its dialysis circuits for treating end-stage renal disease, including dialyzers and blood lines. The original accord in July, 2010 provided for an eight-to-12 [...]

The deal’s the deal at Interface Biologics

Fresh from a potentially game-changing licensing deal with dialysis industry leader Fresenius Medical Care (FSE:FME; NYSE:FMS), closely held Interface Biologics still has more irons in the fire for its biomedical polymers to improve the safety and efficacy of blood-contacting medical devices. “What we’ve tried to do is select a few areas that represent big markets [...]

Interface Biologics licenses Endexo to Fresenius

Closely held Interface Biologics of Toronto has signed an evaluation and exclusive license option agreement with Germany’s Fresenius Medical Care (FSE:FME; NYSE:FMS), the world’s largest provider of dialysis products and services.  Under the accord, Fresenius will evaluate the use and efficacy of Interface’s Endexo technology to various components of its dialysis circuits for treating end-stage [...]

In conversation with Tom Reeves

As CEO of Interface Biologics, Tom Reeves doesn’t dwell on what might have been.  For example, a few years ago, as COO of OccuLogix, he came within the blink of an eye of a billion-dollar breakthrough to treat dry age-related macular degeneration.  That particular opportunity is no more, but Mr. Reeves likes his chances with [...]